The combination of BGB-3111 and obinutuzumab for follicular lymphoma: promising preliminary results
How can we overcome ibrutinib resistance?
Front-line use of ibrutinib for CLL in a real-world setting
Next steps in gaining CLARITY on CLL
Is CLL curable today?